Ionis Pharmaceuticals Shares Drop 23.9% After Phase 3 Eplontersen Trial Misses Endpoint
IONS•Shares of Ionis Pharmaceuticals fell 23.9% to $64.27 following the Phase 3 CARDIO-TTRansform study of eplontersen missing its primary composite endpoint of cardiovascular mortality and recurrent events. The trial, conducted with AstraZeneca in ATTR-CM patients, showed no significant improvement despite a favorable safety profile and subgroup results without transthyretin stabilizers.
1. Phase 3 Trial Miss
The Phase 3 CARDIO-TTRansform study of eplontersen in transthyretin-mediated amyloid cardiomyopathy failed to meet its primary composite endpoint of cardiovascular mortality and recurrent events.
2. Stock Decline Impact
Following the trial results, shares plunged 23.9%, closing at $64.27, marking the largest one-day drop for the company and reflecting investor concerns over the drug’s commercial prospects.
3. Collaboration Insights
Eplontersen, developed in partnership with AstraZeneca, showed a favorable safety profile and nominally significant improvement in a subgroup without transthyretin stabilizers, leaving potential avenues for further research or regulatory discussions.
